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Background: T cell-depletion of haploidentical donor pe-
ripheral blood stem cell (PBSC) products is an important
modality that may expand the donor pool for trans-
plantation in pediatric patients. A survey of pediatric-center
directors shows that many pediatric centers do not have an
on-site stem cell processing laboratory (30%), and many
laboratories do not perform graft manipulation. The suc-
cessful use of cryopreserved grafts from centrally-processed
PBSC collections could expand the availability of this mo-
dality to pediatric centers without on-site stem cell pro-
cessing available.
Methods: Between 2009-2014, PBSCswere collected from 38
mismatched family member donors at Levine Children’sHospital, Charlotte, NC. Seventy PBSC apheresis procedures
were performed on-site for the 38 donor collections. PBSC
products were shipped on frozen gel packs to University of
California (UCSF) Stem Cell Processing Laboratory, per pro-
gram SOP and FACT guidelines. Validated thermal shipping
containers, with FACT compliant shipping labels, and door-
to-door delivery were used. Total costs included an average
$257 to ship each product. The product was inspected and
stored at 4C with next day processing. Processing with the
CD34+ selection by CliniMACS device took one day; prod-
ucts were immediately cryopreserved, then returned on the
day of transplant in a liquid nitrogen dry shipper.
Results: PBSC products were collected for 36 patients. Me-
dian donor age was 29 years (range 12-52). Median number
of apheresis collections was two (range 1-3). 34/36 patients
received a CD34+selected cryopreserved product for 21 ma-
lignant and 15 non-malignant diseases. One patient died
prior to transplant and one elected transplant elsewhere
with a different donor. Pre-processing viability was above
98% on all products. Median post-processing viability was
96% (range 84-99%). Median cell dose infused was
21x106CD34+/kg (range 8-24). There were no adverse events
with infusion. Engraftment (ANC>500) occurred in 33/34
patients, with median engraftment day of 14 days (range 9-
19). One primary graft failure occurred in a leaky-SCID pa-
tient, one secondary graft failure occurred, and both patients
engrafted after a second T cell-depleted mismatched donor
transplant. Shipping costs of PBSC in a dry shipper increased,
from a median $622 in 2009 to $922 in 2014.
Conclusions: An off-site stem cell processing laboratory was
used for CD34+ selection with the CliniMACS device. The
grafts were cryopreserved and shipped for transplant. The
manipulated PBSC grafts from mismatched related family
members were used for successful transplantation with
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portation costs. This experience may improve accessibility to
graft manipulated products for pediatric programs without
an on-site stem cell processing laboratory.183
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Background: About 80% of unrelated, allogeneic donations
for bone marrow transplant are collected as HPC, Apheresis
from peripheral blood using the National Marrow Donor
Program mobilization protocol, BB-IND #6821-0297 for ﬁl-
grastim (Amgen, Thousand Oaks, CA). The aging COBE
Spectra (Terumo, Inc., Golden, CO) was widely used for de-
cades. This collection method pre-dated most predictive
CD34+ counting, and collection orders were written
requesting a run of 24 liters of whole blood. Over-collections
of CD34+cells are seen with this method (mean¼225.17%,
n¼247), often as high as 3X to 6X. Terumo introduced a
replacement apheresis collection device, the Optia, with
updated electronic controls and a different method of
mononuclear cells extraction. The COBE will no longer be
supported in the near future, forcing collection centers to
make a device change.
Problem Statement: The collection efﬁciency of the COBE
device and operators was learned through experience. The
relationship of the previous collection estimation using “li-
ters processed” as a measure for the new device was un-
known. A process to allow training and use on the Optia
device while assuring the patient’s CD34+ cell collection goal
was required.
Materials and Methods: An implementation plan used the
Optia according to manufacturer’s instructions, using only
ACDA as the anticoagulant (no heparin, no aspirin), after staff
training by the vendor. The cell therapy laboratory supported
the implementation by testing the apheresis product at 2
hours into the procedure in order to calculate the size of the
collected product.
Results:
Conclusion: Concurrent CD34+ cell counting facilitated
implementation of the Optia collection method to meet
the collection goals. Frequent over-collection was cor-
rected with yields collections closer to prescription targets
(with slight over collection), mean of 142%. Use of yieldAverage Range






14.655 L  4.848 L 5.596 L e 27.207 L
% to target 142.44 %  60.26 % 61.40 % - 335.17 %





Collection Volume 16.368 L  6.003 L 5.477 L e 24.000 L
% to target 149.08 %  49.46 % 56.88 % - 267.67 %
*Excluded two poorly mobilized outliers, each with a peripheral blood
CD34+ counts of <15x103/mL.information improved collection efﬁciencies from around
20% to 60% with device adjustment. A predictive equation
using pre-CD34+ donor counts was mathematically tested
with the 48 collections and found to be highly predictive.
The average inlet volume was reduced by >40% and the
use of ACDA as the sole anticoagulant further improved
safety for the donor.184
Ex-Utero Plus in Utero Collection of Umbilical Cord Blood
(CB) for Banking Yields Higher Total Nucleated Cell
Counts (TNC) Compared to Either Procedure Alone
Chitra Hosing 1, Mark Munsell 2, Sue Armitage 3,
Tara Sadeghi 3, Katy Rezvani 1, Betul Oran 1, David Marin 1,
Suzanne Dworsky 4, Uday R. Popat 1, Jeffrey Wilson 5,
Amin M. Alousi 1, Nina Shah 1, Amanda Olson 1, Roy B. Jones 1,
Partow Kebriaei 1, Muzaffar H. Qazilbash 1, Simrit Parmar 1,
Ian McNiece 6, Richard E. Champlin 1, Elizabeth J. Shpall 1.
1 Stem Cell Transplantation and Cellular Therapy, The
University of Texas MD Anderson Cancer Center, Houston, TX;
2 Biostatistics, UT MD Anderson Cancer Center, Houston, TX;
3 Cord Blood Bank Program, UT MD Anderson Cancer Center,
Houston, TX; 4 Stem Cell Transplantation Lab, UT MD Anderson
Cancer Center, Houston, TX; 5 Stem Cell Transplantation, UT MD
Anderson Cancer Center, Houston, TX; 6 Stem Cell
Transplantation and Cellular Therapy, MD Anderson Cancer
Center, Houston, TX
Background: Collecting high quality cord blood units
(CBU) is important because the TNC and CD34+ cell dose
of a CBU correlates with transplant outcomes. There are 2
techniques for collecting CBU: while the placenta is still
in-utero by midwives/obstetricians or after placental de-
livery by trained personal (ex-utero). The MD Anderson
Cord Blood Bank uses a combination of the 2 (in+ex utero)
techniques whenever feasible. The aim of this analysis was
to compare the 3 techniques (in-utero, ex-utero, in+ex-
utero).
Methods: CBUs collected between 04/2005 and 7/2011
were retrospectively analyzed. If logistically feasible, an
in-utero collection followed immediately by ex-utero
collection was performed. The total volume, pre- and post-
processing TNC, viable CD34+ cells and microbial
contamination was evaluated in the 3 groups. Analysis of
variance methods was used to compare the 3 groups with
respect to pre- and post-processing TNC and total viable
CD34+ cells. Tukey’s honestly signiﬁcant difference method
was used for pair-wise comparisons of the 3 groups. Mi-
crobial contamination between the groups was compared
using chi square test.
Results: Total of 32,738 CBUs were collected and 23,968
units were processed. The pre-processing TNC was signiﬁ-
cantly higher in the in-utero vs. ex-utero collections. There
was also a signiﬁcantly higher pre-processing TNC in the
in+ex utero collection vs. the in-utero collection. Similar re-
sults were noted in the post-processing TNC. The median
viable CD34+ cells collected were 5.03, 4.26, and 4.93 (x 106)
respectively in the in-utero, ex-utero and in+ex utero groups,
respectively (P< 0.0001 for in-utero vs. ex-utero and ex-
utero vs. in+ex-utero groups). There was no statistically
signiﬁcant difference in the microbial contamination in the
in-utero vs. in+ex utero groups, however it was lower in the
ex-utero collection as compared to either the in-utero or
in+ex utero collections.
Conclusion: We conclude that in+ex utero collection of
umbilical CB for banking is safe and results in signiﬁcantly
higher TNCs than either technique alone.
